Retatrutide FDA Approval Timeline: When Will Retatrutide Be Available?

Where Retatrutide Stands Today (September 2026)

Retatrutide (LY3437943) has completed its pivotal Phase 3 program under Eli Lilly’s TRIUMPH and TRANSCEND programs. It is not approved for any indication in any country. No application has been filed yet; Eli Lilly announced on July 23, 2026 that it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027.

Five positive pivotal Phase 3 readouts are in hand:

• TRIUMPH-4 (December 2025) — first readout: -28.7% mean body weight reduction at 12 mg over 68 weeks in 445 adults with obesity and knee osteoarthritis, plus a 75.8% WOMAC pain reduction at 9 mg.
• TRANSCEND-T2D-1 (April 30, 2026, reported in Eli Lilly’s Q1 2026 earnings release) — first Phase 3 type 2 diabetes data: HbA1c reductions of 1.7-2.0 percentage points and weight loss of 11.1-16.6 kg across doses.
• TRIUMPH-1 (May 21, 2026) — the pivotal obesity trial in 2,339 adults without diabetes: -28.3% at 12 mg/80 weeks (efficacy estimand), with 45.3% of 12 mg participants achieving ≥30% weight loss and the 104-week extension reaching -30.3% in the BMI ≥35 subgroup.
• TRIUMPH-2 (July 23, 2026) — obesity with type 2 diabetes, 1,152 adults: -20.8% at 12 mg/80 weeks and A1C -1.5 points, versus -4.0% and -0.2 on placebo.
• TRIUMPH-3 (July 23, 2026) — severe obesity (BMI ≥35) with established cardiovascular disease, 1,949 adults: -22.6% at 12 mg/80 weeks versus -3.2%; in-study MACE-5 hazard ratio 0.82 (95% CI 0.55–1.22, not significant).

The drug completed Phase 2 trials with results published in the New England Journal of Medicine, demonstrating up to 24.2% body weight reduction at 48 weeks. The Phase 3 results to date have validated and exceeded those signals. Understanding when approval might occur requires examining the regulatory pathway step by step, without overstating the certainty of any timeline.

The TRIUMPH Phase 3 Program

Program Scope

Eli Lilly’s Phase 3 program for retatrutide is one of the largest metabolic drug development programs currently underway. It includes:

• TRIUMPH-1 through TRIUMPH-4: Four pivotal trials evaluating retatrutide for obesity and weight-related conditions across different populations and comorbidities. All four have reported (TRIUMPH-4 December 2025, TRIUMPH-1 May 2026, TRIUMPH-2 and TRIUMPH-3 July 2026).
• TRIUMPH-Outcomes: A separate ~10,000-patient cardiovascular outcomes trial (CVOT) with MACE as primary endpoint
• TRANSCEND: Type 2 diabetes program (TRANSCEND-T2D-1 reported April 2026; TRANSCEND-T2D-2 head-to-head vs semaglutide and TRANSCEND-CKD ongoing)
• SYNERGY / MACELD: Trials evaluating retatrutide for metabolic dysfunction-associated steatohepatitis (MASH), with histological endpoints

The program spans multiple countries, enrolls thousands of participants, and evaluates retatrutide across the full spectrum of metabolic disease — obesity, diabetes, and liver disease.

TRIUMPH-4: First Phase 3 Results

TRIUMPH-4 was specifically designed for adults with obesity and knee osteoarthritis. Key results announced in December 2025:

• Retatrutide 12 mg: -28.7% mean weight loss at 68 weeks
• Retatrutide 9 mg: -26.4% mean weight loss at 68 weeks
• 99% of participants at 12 mg achieved at least 5% weight loss
• 75% reduction in knee osteoarthritis pain scores (WOMAC)
• New safety signal: dysesthesia (abnormal sensory sensations) in 20.9% at 12 mg versus 0.7% placebo

These results validated the Phase 2 signal and provided strong efficacy evidence for regulatory submission. TRIUMPH-4 alone was never going to be sufficient for a submission; the FDA expects multiple pivotal trials, and the dysesthesia signal needed characterization across the program. Both have now happened: dysesthesia at 12 mg was 12.5% in TRIUMPH-1, 7.3% in TRIUMPH-2 and 6.4% in TRIUMPH-3, so the 20.9% in TRIUMPH-4 was the outlier.

Remaining Trial Readouts

As of September 2026 every trial needed for the initial submission has reported. The trials still running are:

• TRANSCEND-T2D-2 (head-to-head vs semaglutide in T2D): Ongoing
• TRANSCEND-CKD (T2D + chronic kidney disease): Ongoing
• SYNERGY / MACELD (MASH, histological endpoints): Multi-year duration
• TRIUMPH-Outcomes (cardiovascular outcomes trial): Multi-year event-driven trial; post-approval timeline
• Chronic low back pain (Phase 3): Ongoing, per Lilly’s August 5, 2026 earnings call

On July 23, 2026 Eli Lilly said it “plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027” for obesity, knee osteoarthritis pain and obstructive sleep apnea. On its August 5 earnings call the company said the clinical package is complete and the remaining work is on the manufacturing (CMC) side. Two things changed from earlier guidance: the date slipped from “late 2026” to Q1 2027, and the application is a BLA rather than an NDA.

Why a BLA, and why it matters

Lilly’s position is that retatrutide, a 41-amino-acid peptide, is a biologic. A BLA carries 12 years of data exclusivity rather than five, and biologics fall outside the pharmacy-compounding provisions that apply to drugs. The FDA has treated retatrutide as a drug and the two sides are in court: a district court found the peptide does not meet the strict statutory definition of a protein but that the FDA’s reasoning on the “analogous to a protein” question was arbitrary, and Lilly’s appeal (Eli Lilly v. Kennedy) is before the Seventh Circuit, with oral argument on September 24, 2026. The review clock is the same either way; the outcome matters for exclusivity and compounding after approval.

The Regulatory Pathway: Step by Step

Drug approval follows a well-established sequence, each step with its own typical duration:

Step 1: Phase 3 Data Collection and Readout (Current Stage)

Pivotal trials typically run 68-72 weeks for obesity indications. Including enrollment time, data collection, and analysis, the interval from Phase 3 initiation to primary data readout is generally 2-3 years. TRIUMPH-4 has reported, and initial results from other TRIUMPH trials are anticipated in late 2026 to 2027.

Step 2: Application Preparation and Submission

After positive Phase 3 results, the sponsor compiles the complete data package into a marketing application (a BLA in retatrutide’s case). This typically takes 6-12 months after the last primary readout; Lilly’s plan of a Q1 2027 submission is about eight months after the July 2026 TRIUMPH-2/3 readouts.

For the obesity indication, the submission will draw on all four TRIUMPH trials plus the complete safety database. BLA filing is planned for Q1 2027.

Step 3: FDA Review

The FDA first takes up to 60 days to decide whether to accept the application for filing. From the filing date, standard review is 10 months and Priority Review is 6 months, so a Q1 2027 submission yields a decision date in late 2027 (Priority) or the first half of 2028 (Standard).

• Standard Review: 10 months from filing (about 12 months from submission)
• Priority Review: 6 months from filing (about 8 months from submission)

Priority Review is granted when a drug offers a significant improvement over available therapy for a serious condition. Given the magnitude of retatrutide’s weight loss and the potential MASLD benefit, Priority Review is plausible but not guaranteed.

Step 4: Advisory Committee Meeting

The FDA may convene an advisory committee (AdCom) of independent experts to evaluate the application. This is not always required but is common for novel mechanisms. The advisory committee reviews efficacy data, safety concerns (including the dysesthesia signal), and the overall benefit-risk profile. The AdCom provides a recommendation, but the FDA is not bound by it.

Step 5: FDA Decision (PDUFA Date)

The FDA sets a target action date (the PDUFA date) when it commits to completing its review. The agency will either approve the drug, issue a Complete Response Letter requesting additional information, or (rarely) deny approval outright.

Realistic Timeline Estimates

Optimistic Scenario (Late 2027)

This scenario assumes:

• BLA submitted in Q1 2027, per Eli Lilly’s July 2026 guidance
• Priority Review designation is granted (6-month review)
• No major safety signals beyond dysesthesia, which is adequately characterized
• Clean FDA review with no major information requests

Base Case Scenario (First Half of 2028)

This is the most likely timeline:

• BLA submitted in Q1 2027
• Standard Review (10 months from filing)
• FDA approval in the first half of 2028

Delayed Scenario (2028 or Later)

Possible if:

• Dysesthesia signal requires additional safety studies
• FDA requests a cardiovascular outcomes trial before approval
• Manufacturing or supply chain issues delay submission
• Enrollment delays push trial readouts later than expected

How This Compares to Tirzepatide and Semaglutide

Examining the timelines of recently approved metabolic drugs provides useful context:

Semaglutide (Wegovy)

Novo Nordisk published the STEP 1 Phase 3 obesity results in February 2021. The FDA approved Wegovy in June 2021 — an unusually fast turnaround enabled by prior approval of semaglutide for diabetes (Ozempic) and rolling NDA submission. The total development time from first-in-human to obesity approval was approximately 6 years.

Tirzepatide (Zepbound)

Eli Lilly published the SURMOUNT-1 Phase 3 obesity data in mid-2022. Zepbound received FDA approval for obesity in November 2023, approximately 17 months later. This was expedited by prior diabetes approval (Mounjaro in May 2022), which established the safety database and manufacturing infrastructure.

Retatrutide: Key Difference

A critical difference for retatrutide is that it does not yet have approval in any indication. Without a prior diabetes approval to build upon, the first retatrutide approval may take somewhat longer than the obesity approvals for semaglutide and tirzepatide. The FDA will need to evaluate the entire safety database from scratch, including the novel glucagon receptor component and the dysesthesia signal.

Potential for Expedited Pathways

Several factors could accelerate retatrutide’s path:

• Breakthrough Therapy Designation: If the FDA determines that retatrutide may offer substantial improvement over existing treatments, this designation provides more intensive FDA guidance, organizational commitment, and potentially faster review. The -28.7% weight loss in TRIUMPH-4 and the unique triple receptor mechanism could support such a designation.
• Rolling submission: Eli Lilly could submit sections of the application as they are completed rather than waiting for the complete package, reducing the gap between data readout and submission acceptance.
• Priority Review: Possible given the significant unmet need, particularly for MASLD where approved treatments are limited.
• Accelerated Approval (for MASH): If SYNERGY demonstrates histological improvement, an accelerated approval pathway for the MASH indication could be explored, though this would likely be separate from the obesity filing.

Multiple Indications, Multiple Timelines

Different indications will likely follow different regulatory timelines:

• Obesity: Most likely the first indication, given commercial precedent and regulatory familiarity with weight management approvals. Estimated approval: late 2027 to the first half of 2028, based on the BLA filing planned for Q1 2027.
• Type 2 diabetes: Could follow closely after the obesity approval, using the TRANSCEND data. Estimated approval: late 2027-2028.
• MASH: May require longer trials with histological endpoints and faces a less established regulatory pathway. The SYNERGY trial could support approval, but timing depends on study duration and regulatory requirements. Estimated approval: 2029 or later.

Latest Milestones as of September 2026

What Needs to Happen Before Approval

For patients wondering “when will retatrutide be available,” here is what must still occur:

1. Remaining Phase 3 trials must report results Done. All five pivotal trials reported between December 2025 and July 2026.
2. Safety database must be compiled: The FDA requires a comprehensive safety analysis across all trials.
3. Dysesthesia must be characterized Done in the topline data: 12.5%, 7.3% and 6.4% at 12 mg in TRIUMPH-1, -2 and -3 versus 20.9% in TRIUMPH-4; the full presentations will add detail on severity and reversibility.
4. BLA must be prepared and submitted: Lilly says the clinical data are complete and manufacturing (CMC) data are being finalized for a Q1 2027 submission.
5. FDA must complete its review: 6-12 months depending on review pathway.
6. Manufacturing must be scaled: Commercial-scale production of retatrutide must be established and validated.

Frequently Asked Questions About Retatrutide Approval

When will retatrutide be approved?

The most realistic estimate for FDA approval is the first half of 2028, with an optimistic scenario of late 2027 if Priority Review is granted. Eli Lilly said on July 23, 2026 that it plans to submit a BLA in Q1 2027. The timeline is subject to change.

Has Eli Lilly filed for FDA approval of retatrutide?

No. As of September 2026, no application has been filed with the FDA for retatrutide. All five pivotal Phase 3 readouts are in hand (TRIUMPH-4, TRANSCEND-T2D-1, TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3), and Eli Lilly plans to submit a Biologics License Application in Q1 2027.

Will retatrutide get Priority Review from the FDA?

It is possible but not guaranteed. Priority Review is granted when a drug offers significant improvement over available therapy for a serious condition. Retatrutide’s -28.7% weight loss in TRIUMPH-4 and its unique triple receptor mechanism could support a Priority Review designation, which would shorten the FDA review period from 10 months to 6 months after filing.

Can I get retatrutide through a clinical trial?

Clinical trial enrollment is the main legitimate way to access retatrutide; since August 2026 Lilly also runs a narrow expanded access program for adults with severe, refractory obesity, which a physician must request. Visit ClinicalTrials.gov and search for “retatrutide” or “LY3437943” to find active trials. Eligibility criteria vary by trial, and participants may be randomized to placebo.

Why is drug approval so slow?

The FDA approval process is designed to ensure that medications are both safe and effective before being made available to the public. Phase 3 trials must enroll thousands of participants, treat them for extended periods (often 68+ weeks), collect and analyze data, and demonstrate an acceptable benefit-risk profile. This process protects patients but inherently takes time — typically 2-3 years for Phase 3 alone, followed by 6-12 months of FDA review.

What Patients and Clinicians Should Know

The most important message is that retatrutide is not yet available and will not be for at least 1-2 years. Patients should:

• Work with their healthcare providers on currently approved treatment options (Wegovy, Zepbound, etc.)
• Not purchase unregulated “retatrutide” from online sources — these products are not FDA-approved, not quality-controlled, and potentially dangerous
• Consider clinical trial enrollment as the main legitimate route to access retatrutide, via ClinicalTrials.gov (expanded access exists but is limited to severe, refractory obesity)
• Monitor Eli Lilly’s public announcements for Phase 3 data updates

Timelines in drug development are inherently uncertain. The estimates provided here are based on typical regulatory patterns and publicly available information, but actual events may diverge significantly in either direction.

Key Takeaways

• Current status: Pivotal Phase 3 program complete; five positive readouts between December 2025 and July 2026
• Not approved: No regulatory authority has approved retatrutide for any indication
• Nothing filed yet: Eli Lilly plans a Biologics License Application in Q1 2027
• Headline results: -28.7% (TRIUMPH-4), -28.3% (TRIUMPH-1), -20.8% in diabetes (TRIUMPH-2), -22.6% with cardiovascular disease (TRIUMPH-3)
• Remaining steps: BLA preparation (CMC data), FDA filing review and review, possible advisory committee, resolution of the biologic-classification dispute
• BLA filing: Q1 2027 (per Eli Lilly, July 23 and August 5, 2026)
• Best estimate for approval: First half of 2028 (base case), late 2027 (optimistic, Priority Review)
• How to access now: Clinical trials via ClinicalTrials.gov, or Lilly’s expanded access program for severe refractory obesity
• Warning: Avoid unregulated online sources claiming to sell retatrutide